Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

INTRODUCTION: Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion. Previously published pre-clinical data suggest that dapagliflozin lacks carcinogenic potential. This article r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575305/
https://www.ncbi.nlm.nih.gov/pubmed/26323372
http://dx.doi.org/10.1007/s13300-015-0128-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575305/
https://www.ncbi.nlm.nih.gov/pubmed/26323372
http://dx.doi.org/10.1007/s13300-015-0128-9

Ejemplares similares